BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)

NCT00101413 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer
Carcinoma, Non-Small Cell Lung

Interventions

DRUG: Sorafenib (Nexavar, BAY43-9006)

Sponsor

Bayer

Collaborators

[object Object]